Copyright ©2016 MBD                                 Specification and product names are trademarks or trade names of their respective companies or organizations.

Please reload

Recent Posts

Unified 2D and 3D cell-based high-throughput screening platform using a micropillar/microwell chip

January 11, 2016

Please reload

Featured Posts

High-Throughput, miniaturized clonogenic analysis of limiting dilution assay on a micropillar/microwell chip with brain tumor cells

December 29, 2014

Small, 10(24) (29 Dec 2014) 5098-5105.


The limiting dilution assay (LDA) is a clonogenic drug efficacy test designed to determine a value for drug efficacy based on an all-or-none (positive or negative) response within replicates. It also attempts to calculate minimum cell numbers for cells to form colony in each drugged conditions, wherein a large value implies high drug efficacy (as a large number of extant cells are required to start a colony). 

However, traditional LDAs are time-consuming to set up, often requiring many replicates for statistical analysis, and manual colony identification under a microscope to determine a positive or negative response is tedious and is susceptible to human error.

To address these issues, a high-throughput miniaturized LDA assay is developed using a micropillar/microwell chip platform using an automatic colony identification method. Three glioblastoma multiforme (GBM) brain tumor isolates (448T, 464T, and 775T) are used to test this new assay, using the c-Met kinase inhibitors SU11274 and PHA665752 as the target drugs. The results show that the minimum cell number of 775T is larger than that of the other two cell types (SU11274 and PHA665752) in both the sampled drugs, a result that is in good agreement with the results of previous conventional experiments using 96 well plates.


[ + Click ]

Please reload

Please reload

Search By Tags